Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|HER2-positive Breast Cancer
Interventions: DRUG: PHESGO
Sponsor: Latin American Cooperative Oncology Group
Collaborators: Roche Pharma AG|Oncoclínicas